A Multiple Dose Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of ABT-652 Administered Once Daily in Subjects With an Excessive Daytime Sleepiness Disorder
| City: |
|
Phoenix |
| State: |
|
Arizona |
| Zip Code: |
|
85006 |
| Conditions: |
|
Sleep Disorder |
| Purpose: |
|
The main purpose of this study is to evaluate the safety and tolerability of the drug
ABT-652 given once daily to people with excessive daytime sleepiness. Subjects will be
randomized to either ABT-652 or placebo in three sequential dosing groups for a 1-week
treatment period.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Has current diagnosis of an excessive daytime sleepiness disorder, including
narcolepsy, idiopathic hypersomnia, and obstructive sleep apnea
- Age 18 to 60 years
Exclusion Criteria:
- Has significant suicidal ideation
- Has a history of substance abuse
- Has a history of a certain significant medical conditions, including uncontrolled
psychiatric diseases or disorders
- Use of certain medications
|
| NCT ID: |
|
NCT01124851 |
| Primary Contact: |
|
Susan Mattingly
Phone: (847) 935-7233
Email: Susan.Mattingly@abbott.com
|
| Backup Contact: |
|
Email: Randall.Avers@abbott.com
Randall Avers
Phone: (847) 938-8973
|
| Location Contact: |
|
Phoenix, Arizona 85006
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 20, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|